Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (555)	3/30/1998 9:00:00 PM
From: Pancho Villa	Respond to of 4634

>Checkup on the DOOM INDEX (tm)< Not bad. BTW, Jill provided excellent advice on the question I posed to you the other day. Still short TRBO. Pancho

To: Bill Wexler who wrote (555)	3/31/1998 3:43:00 PM
From: Jim Roof	Read Replies (1) \| Respond to of 4634

Bill, You mentioned a rumor that was false regarding Biotime's submittal of the NDA by the end of March. At least I remember you saying that it was false. ################################################################ NDA: BERKELEY, Calif.--(BW HealthWire)--March 31, 1998--BioTime, Inc. (NASDAQ:BTIM - news) today announced that it has completed the submission of its New Drug Application (NDA) for Hextend(R), BioTime's proprietary blood plasma volume expander. .... Entire text: biz.yahoo.com ################################################################ You were wrong. It was neither a rumor nor false. It was the company making good on their goal of submission by month's end. Jim